The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
22 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $9,870,348 in first-year total cost, median $476,388.
Most frequent study sections
- Special Emphasis Panel[ZRG1 EMNR-R (56)]19
- Special Emphasis Panel[ZRG1-EMNR-R(56)R]3
Most frequent institutions
- RESEARCH TRIANGLE INSTITUTE2
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2
- WASHINGTON UNIVERSITY2
- BETH ISRAEL DEACONESS MEDICAL CENTER1
- DARTMOUTH COLLEGE1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | SMALL MOLECULE BACTERIAL LECTIN ANTAGONISTS FOR UTI TREATMENT AND PREVENTION1R01DK108840-01A1 | HULTGREN, SCOTT J.JANETKA, JAMES W | WASHINGTON UNIVERSITY, MO | $485,650 | ZRG1 |
| 2017 | APJ receptor agonism for metabolic syndrome1R01DK103625-01A1 | MAITRA, RANGAN | RESEARCH TRIANGLE INSTITUTE, NC | $471,450 | ZRG1 |
| 2016 | A PSGL-1 Glycopeptide Mimetic for Treatment of Metabolic Syndrome1R01DK107405-01 | CHAIKOF, ELLIOTKAHN, BARBARA B. | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $638,976 | ZRG1 |
| 2016 | Xanthine oxidase inhibition raises intracellular purines to activate AMPK, improve glucose control and decrease fatty liver and atherosclerosis in type 2 diabetes1R01DK108936-01 | SHOELSON, STEVEN E | JOSLIN DIABETES CENTER, MA | $413,750 | ZRG1 |
| 2016 | Pre-clinical studies to explore the therapeutic potential of insulin-degrading enzyme inhibitors1R56DK106200-01A1 | SAGHATELIAN, ALANSEELIGER, MARKUS A | SALK INSTITUTE FOR BIOLOGICAL STUDIES, CA | $331,500 | ZRG1 |
| 2016 | Validation of Aconitase-Isocitrate Pathway as a Target for Anemia Treatment1R01DK101550-01A1 | GOLDFARB, ADAM N. | UNIVERSITY OF VIRGINIA, VA | $237,000 | ZRG1 |
| 2016 | Preclinical Development of Khellin Analogs for Anti-Diabetic Therapy1R56DK108887-01A1 | WANG, WEIDONG | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $222,000 | ZRG1 |
| 2015 | Preclinical validation of ABHD5 as a target for treatment of obesity.1R01DK105963-01 | GRANNEMAN, JAMES G | WAYNE STATE UNIVERSITY, MI | $686,724 | ZRG1 |
| 2015 | Small Molecule Inhibitors of LMPTP: An Obesity Drug Target1R01DK106233-01 | BOTTINI, NUNZIOPINKERTON, ANTHONY BRUCE | LA JOLLA INSTITUTE FOR IMMUNOLOGY, CA | $633,892 | ZRG1 |
| 2015 | Eicosanoid-based Therapy for Diabetes1R01DK103616-01A1 | IMIG, JOHN D | MEDICAL COLLEGE OF WISCONSIN, WI | $485,131 | ZRG1 |
| 2015 | Validation of small molecule 12-lipoxygenase inhibitors in metabolic disease1R01DK105588-01 | MIRMIRA, RAGHAVENDRA GNADLER, JERRY L. | INDIANA UNIVERSITY INDIANAPOLIS, IN | $481,326 | ZRG1 |
| 2015 | Activating cystic fibrosis transmembrance conductance regulator: the therapeutic potential of RNA directed gene activation1R01DK104681-01 | MORRIS, KEVIN V | SCRIPPS RESEARCH INSTITUTE, THE, CA | $413,735 | ZRG1 |
| 2015 | TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITIS1R01DK104735-01 | FINCK, BRIAN N | WASHINGTON UNIVERSITY, MO | $410,065 | ZRG1 |
| 2015 | Targeting Diabetes With Novel Small Molecule Therapeutics1R56DK100624-01A1 | LEBECHE, DJAMEL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $169,500 | ZRG1 |
| 2014 | IKKepsilon/TBK1 Inhibitors for the Treatment of Obesity and Type 2 Diabetes1R01DK100319-01 | SALTIEL, ALAN R. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $594,912 | ZRG1 |
| 2014 | Designed Small Molecule Inhibitors of Ghrelin O-Acyl Transferase1R01DK100627-01A1 | HARRAN, PATRICK G.TONTONOZ, PETER J | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $554,272 | ZRG1 |
| 2014 | Pharmacological Validation of IRE1 for Diabetes Mellitus1R01DK100623-01 | MALY, DUSTIN JPAPA, FEROZ R | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $501,998 | ZRG1 |
| 2014 | Preclinical Validation of Transglutaminase 2 as a Novel Target for Celiac Disease1R01DK100619-01A1 | KHOSLA, CHAITAN | STANFORD UNIVERSITY, CA | $482,228 | ZRG1 |
| 2014 | Preclinical development of CFTR stabilizers targeting the CAL PDZ domain1R01DK101541-01 | MADDEN, DEAN R | DARTMOUTH COLLEGE, NH | $482,128 | ZRG1 |
| 2014 | Therapeutics Development for Hepatic Fibrosis1R01DK100414-01A1 | MAITRA, RANGAN | RESEARCH TRIANGLE INSTITUTE, NC | $450,143 | ZRG1 |
| 2014 | Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics1R01DK103658-01 | HOPKINS, COREY R. | VANDERBILT UNIVERSITY, TN | $368,055 | ZRG1 |
| 2014 | Urea transport inhibitors as a new class of diuretics1R01DK101373-01 | VERKMAN, ALAN S | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $355,913 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.